Elanco Animal Health INC Form 4 insider transactions

Director William F. Doyle of Elanco Animal Health Inc. received 18,169 shares of common stock as part of an annual equity award.

Director Kapila K. Anand of Elanco Animal Health Inc. received 18,169 shares of common stock as part of an annual equity award.

Denise Scots-Knight, a director at Elanco Animal Health, received 18,169 shares of common stock as part of an annual equity award.

Elanco Animal Health director John P. Bilbrey received a grant of 18,169 deferred stock units and disposed of 78,400 common shares held in a revocable trust.

R. David Hoover, a director at Elanco Animal Health, reported the acquisition of 18,169 shares of common stock and the disposal of 185,000 shares held in a revocable trust.

Stacey Ma, a director at Elanco Animal Health, received 2,539 shares of common stock as part of an annual equity award.

Director Kathy V. Turner of Elanco Animal Health Inc. received 13,838 shares of common stock as part of an annual equity award.

Craig S. Wallace, a director at Elanco Animal Health, acquired 13,838 shares of common stock through a grant of deferred stock units.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, acquired 104,816 deferred stock units on November 29, 2024.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired 209.6321 deferred stock units, convertible to common stock, on November 29, 2024.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired 198.0858 deferred stock units, convertible to common stock, on November 15, 2024.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, acquired 99.0429 deferred stock units on November 15, 2024.

Elanco Animal Health's CEO, Jeffrey N. Simmons, reported the acquisition of deferred stock units on November 1, 2024.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units on November 1, 2024.

Elanco Animal Health CEO Jeffrey N. Simmons acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, reports the acquisition of deferred stock units convertible to common stock or cash.

Elanco Animal Health's CEO, Jeffrey N. Simmons, reported the acquisition of deferred stock units on October 4, 2024.

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, reports the acquisition of deferred stock units convertible to common stock, according to a Form 4 filing with the SEC.

Director Lawrence Kurzius reports acquisition of deferred stock units through Elanco's Directors' Deferral Plan.

Executive Vice President of Elanco Animal Health, Rajeev A. Modi, reports the acquisition of deferred stock units convertible to common stock or cash.

Elanco Animal Health's CEO, Jeffrey N. Simmons, reports acquiring deferred stock units convertible to common stock or cash.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units representing the right to receive common stock or cash equivalent.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC Form 4 filing.

Jeffrey N. Simmons, CEO of Elanco Animal Health, reports acquisition of deferred stock units.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported changes in beneficial ownership related to deferred stock units.

Director Michael J. Harrington of Elanco Animal Health Inc. purchased 3,500 shares of common stock on August 22, 2024.

Elanco Animal Health's CEO, Jeffrey Simmons, recently purchased 100,000 shares of the company's common stock at an average price of $13.0061 per share.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Elanco Animal Health's CEO, Jeffrey N. Simmons, reports the acquisition of deferred stock units convertible to common stock.

Elanco Animal Health's CEO, Jeffrey N. Simmons, reports the acquisition of deferred stock units on July 26, 2024.